



OMT and OMTT selected to present at the Cavendish Global Health Impact Forum

Palo Alto, CA, March 30, 2015

Open Monoclonal Technology, Inc. (OMT) and Open Monoclonal Technology Therapeutics, Inc. (OMTT) today announced that they have been selected to present at the Cavendish Global Health Impact Forum May 10-14 in La Jolla, California. The Forum serves to help family offices and foundations develop and implement their individual pro-social impact investing, grant-giving, and philanthropy programs within health and the life sciences. Three times a year it showcases leading research institutions, accomplished healthcare delivery professionals, health-policy experts and private-sector companies engaged in development of innovations with potential for transformational impact on disease prevention, diagnosis and treatment. The next Forum is being co-hosted by the community of La Jolla, California including The University of California San Diego, The J. Craig Venter Institute, The Scripps Research Institute, The Sanford-Burnham Medical Research Institute, The Sanford Consortium for Regenerative Medicine, and The Institute of the Americas.

Michael Moffat, Cavendish co-founder and Chief Executive Officer explains, “The theme of our La Jolla, California Forum is ‘Celebration of Philanthropy, Impact Investing and Innovation that is Changing the World.’ With the help of our expert advisors, we conduct a global search of research institutions and private-sector companies in order to identify organizations that meet the required standard of excellence. The quality and originality of OMT and OMTT in transgenic animal-based, fully human antibody therapeutics positions them, via their extensive network of biopharmaceutical partners globally, to make a major contribution across of a wide range of human diseases.”

Dr. Roland Buelow, founder of OMT and OMTT, commented, “We are honored that Cavendish Global recognizes OMT’s and OMTT’s unique ability to enable world-leading biopharmaceutical companies develop mono-, bi- and poly-specific human antibodies for a wide range of human diseases using transgenic animals. We look forward to interacting with accomplished scientists, thought-leaders and generous philanthropic individuals and families who are all dedicated to the common cause of improving the health and lives of people around the world.”

About Cavendish Global

Cavendish Global consists of leading family offices and foundations from around the world with combined assets of over \$190 billion who share a passion for pro-social endeavors within health and the life sciences. The Cavendish Global Health Impact Forum provides family offices with a discrete, peer-to-peer knowledge expansion and relationship building environment, combined with the information and educational resources required by foundations actively seeking to accelerate technological innovation and health access through sustainable philanthropy, grant-making and impact investing. The Forum is also an opportunity for family offices to champion and share information on projects and organizations, which they are passionate about with other family offices from around the world. For more information, please visit <http://cavendishglobal.com> or

contact Alex Charlton, Cavendish Global President, at phone +1-917-576-1435 or E-mail alex.charlton@cavendishglobal.com.

About Open Monoclonal Technology and Open Monoclonal Technology Therapeutics

Open Monoclonal Technology, Inc. (OMT) and Open Monoclonal Technology Therapeutics, Inc. (OMTT) are leaders in genetic engineering of animals for generation of human therapeutic antibodies, *naturally optimized human antibodies*[®], and the only company in the world with four transgenic animal platforms, jointly *OmniAb*[™].

OmniRat[®] is the industry's first human monoclonal antibody technology based on rats. It has a complete immune system with a diverse antibody repertoire and generates antibodies with human idiotypes as well as wild-type animals make rat antibodies. *OmniMouse*[®] is a transgenic mouse that complements OmniRat and expands epitope coverage. *OmniFlic*[™] is an engineered rat with a fixed light chain for development of bispecific, fully human antibodies. *UniRat*[™] is the first transgenic rat generating fully human heavy chain-only antibodies and nanobodies for polyspecific applications.

All four *OmniAb*[™] platforms deliver human antibodies with high affinity, specificity, expression, solubility and stability. They use patented technology, have broad freedom to operate and are available worldwide for all targets and indications. Current partners include Celgene, Chugai, Genmab, Genentech, HanAll, Janssen, Merck KGaA, Pfizer, Roche, Symphogen, an undisclosed global pharmaceutical company and several smaller biotech companies and universities. *OmniAb* antibody discovery services are available via Antibody Solutions in the US, Aldevron in Germany and WuXi AppTec in China.

For more information, please visit www.omtinc.net or contact Chief Business Officer, Brian Lundstrom, at phone +1-775-420-7750 or E-mail: bl@omtinc.net.